Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1983 2
1984 1
1985 4
1986 1
1987 2
1988 6
1989 1
1990 1
1991 10
1992 3
1993 4
1994 9
1995 5
1996 6
1997 16
1998 11
1999 14
2000 12
2001 20
2002 19
2003 24
2004 25
2005 29
2006 52
2007 61
2008 72
2009 89
2010 111
2011 120
2012 133
2013 139
2014 209
2015 244
2016 239
2017 210
2018 265
2019 322
2020 371
2021 369
2022 488
2023 460
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

3,715 results

Results by year

Filters applied: . Clear all
Page 1
A Roadmap for the Human Gut Cell Atlas.
Zilbauer M, James KR, Kaur M, Pott S, Li Z, Burger A, Thiagarajah JR, Burclaff J, Jahnsen FL, Perrone F, Ross AD, Matteoli G, Stakenborg N, Sujino T, Moor A, Bartolome-Casado R, Bækkevold ES, Zhou R, Xie B, Lau KS, Din S, Magness ST, Yao Q, Beyaz S, Arends M, Denadai-Souza A, Coburn LA, Gaublomme JT, Baldock R, Papatheodorou I, Ordovas-Montanes J, Boeckxstaens G, Hupalowska A, Teichmann SA, Regev A, Xavier RJ, Simmons A, Snyder MP, Wilson KT; Gut Cell Atlas Consortium; Human Cell Atlas Gut Biological Network Consortium. Zilbauer M, et al. Among authors: xie b. Nat Rev Gastroenterol Hepatol. 2023 Sep;20(9):597-614. doi: 10.1038/s41575-023-00784-1. Epub 2023 May 31. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37258747 Free PMC article. Review.
EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer.
Li K, Tan G, Zhang X, Lu W, Ren J, Si Y, Adu-Gyamfi EA, Li F, Wang Y, Xie B, Wang M. Li K, et al. Among authors: xie b. Biomolecules. 2022 Nov 26;12(12):1756. doi: 10.3390/biom12121756. Biomolecules. 2022. PMID: 36551184 Free PMC article.
Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons.
Qian J, Guan X, Xie B, Xu C, Niu J, Tang X, Li CH, Colecraft HM, Jaenisch R, Liu XS. Qian J, et al. Among authors: xie b. Sci Transl Med. 2023 Jan 18;15(679):eadd4666. doi: 10.1126/scitranslmed.add4666. Epub 2023 Jan 18. Sci Transl Med. 2023. PMID: 36652535
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Among authors: xie b. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.
A neurodevelopmental epigenetic programme mediated by SMARCD3-DAB1-Reelin signalling is hijacked to promote medulloblastoma metastasis.
Zou H, Poore B, Brown EE, Qian J, Xie B, Asimakidou E, Razskazovskiy V, Ayrapetian D, Sharma V, Xia S, Liu F, Chen A, Guan Y, Li Z, Wanggou S, Saulnier O, Ly M, Fellows-Mayle W, Xi G, Tomita T, Resnick AC, Mack SC, Raabe EH, Eberhart CG, Sun D, Stronach BE, Agnihotri S, Kohanbash G, Lu S, Herrup K, Rich JN, Gittes GK, Broniscer A, Hu Z, Li X, Pollack IF, Friedlander RM, Hainer SJ, Taylor MD, Hu B. Zou H, et al. Among authors: xie b. Nat Cell Biol. 2023 Mar;25(3):493-507. doi: 10.1038/s41556-023-01093-0. Epub 2023 Feb 27. Nat Cell Biol. 2023. PMID: 36849558 Free PMC article.
BCL6 promotes a stem-like CD8+ T cell program in cancer via antagonizing BLIMP1.
Sun Q, Cai D, Liu D, Zhao X, Li R, Xu W, Xie B, Gou M, Wei K, Li Y, Huang J, Chi X, Wei P, Hao J, Guo X, Pan B, Fu Y, Ni L, Dong C. Sun Q, et al. Among authors: xie b. Sci Immunol. 2023 Oct 27;8(88):eadh1306. doi: 10.1126/sciimmunol.adh1306. Epub 2023 Oct 20. Sci Immunol. 2023. PMID: 37862431
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X, Sun L, Song N, He W, Xie B, Hu J, Zhang J, Yang J, Dai J, Bian D, Xia H, Sun F, Xiong A, Luo J, Zhang L, Yu H, Liu M, Liu H, Wang H, Zhang H, Chen C, Wu C, Duan L, Zhu Y, Zhang P, Jiang G. Zhu X, et al. Among authors: xie b. BMC Med. 2022 Dec 30;20(1):493. doi: 10.1186/s12916-022-02696-4. BMC Med. 2022. PMID: 36581917 Free PMC article. Clinical Trial.
3,715 results